Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
The panel provides comprehensive insights on the treatment of ICANS following CAR T-cell therapy, highlighting the role of imaging, clinical trial data, and clinical pearls for community practices.
EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach
EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
EP: 4.Underlying Mechanisms and Signs of CRS
EP: 5.Strategies to Manage or Mitigate CRS
EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
Now Viewing
EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management
EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients
EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
Video content above is prompted by the following questions:
- What do you consider best practices for the management of ICANS following CAR T-cell therapy?
- What are some strategies you can use to manage or mitigate ICANS in patients receiving CAR T-cell therapy?
Recent Videos
Related Content
